Take AIM at complex drug formulation
We use advanced AI modeling to reduce your experimentation, spend, and time to market
Traditional drug formulation and reformulation take years, hundreds of experiments, and millions of dollars. It is extraordinarily difficult to map the chemistry, process variables, pharmacokinetics, bioequivalence, and clinical endpoints in a manner that tells you which formulations are likely to succeed and why.
Fewer failed experiments. Faster timelines. Decisions backed by real data.
Learn About Our Vision & ProgressOne partner from modeling
to manufacturing
Advanced causal AI technology
works to solve your formulation challenge, modeling the chemistry and directing experimentation toward what matters most
Our technologists
build the models and manage the data behind every program
Our pharmaceutical veterans
source and manage the right CROs and CDMOs to execute wet lab testing and manufacturing
A better way to formulate drugs
Every drug formulation project has different starting points, challenges, and timeline pressures. Whether you’re working to generate new intellectual property for molecules nearing patent expiration, untangling a complex generic, rescuing a failed program, or formulating an entirely new drug, Allos will guide your journey from molecule to marketed drug product.
-
Waning patent life doesn’t have to mean diminishing portfolio value. Allos models new drug formulations, delivery routes, and dosing strategies that extend patent life and strengthen your portfolio.
-
Complex generics demand precise bioequivalence, so Allos models the chemistry up front, cutting the guesswork and experiments needed to reach the best solutions.
-
A failed bioequivalence or stability study doesn’t have to end a program. Allos identifies what went wrong and quickly establishes a path to a successful formulation.
-
Have a molecule and a target, and looking to support your formulation team? Allos maps the delivery pathway, from dosage form to route of administration, so your NCE reaches the clinic faster.
From costly, failure-prone iteration to a strategic path
Traditional formulations’ lengthy cycles of iteration cost innovator and generic drug companies missed opportunities and led to unnecessarily high budgets. Allos’s advanced AI modeling shaves years from timelines and saves millions.
Drug Formulation Today
Formulation Path Optimization Avoids Trial and Error Iteration
We take Drug Formulation from an Iterative, Failure-prone Process to a Highly Optimized Map
Allos AI Modeling In Action
01
02
03
04
Success Story: AI-driven stabilization of an oral Liquid
challenge
An oral liquid formulation faced three compounding risks: oxidative degradation from lipid excipients causing API impurities, physical instability from phase separation and temperature-sensitive viscosity, and a preservative system undermined by the high pH needed to protect the API.
approach
Allos flagged high-risk unsaturated oils and peroxide-forming surfactants driving oxidation, and recommended low-peroxide excipient sourcing, antioxidant addition, and oxygen-controlled packaging. It identified the preservative’s reduced effectiveness at high pH and proposed a dual-preservative strategy alongside polymeric stabilizers and optimized homogenization to prevent phase separation.
outcome
The client moved forward with a formulation strategy addressing all three instability risks before committing to stability studies, backed by a validated preservative system and a dosing-consistent physical formulation, avoiding the late-stage surprises that typically surface only after batches are made.
New era of drug development
Allos combines advanced AI modeling with your CMC data to define the Target Product Profile (TPP) before formulation begins, replacing guesswork with a validated path forward. Explore how this approach reduces risk at every stage and keeps you ahead on regulatory and quality requirements.
De-Risking Drug Formulation
We model your molecule’s chemistry, process variables, and performance data up front, identifying formulation risks before they lead to failed experiments, missed timelines, or wasted budget, so every decision moving forward is backed by evidence.
Regulatory & Quality
Allos’s causal AI traces every formulation decision back to its reasoning, giving regulators and quality teams a transparent, auditable record that shows not just what was decided, but why.
How the Allos causal AI platform guides workflows
Let's Model Your Next Success
Whether you're facing patent expiration, a failed study, or a molecule with nowhere to go yet, Allos can show you a faster, evidence-backed path forward.